Ifg Advisory, LLC Exelixis, Inc. Transaction History

Ifg Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 05, 2018	SELL	$15.87 - $22.4 $284,041 - $400,915	-17,898 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$18.56 - $22.45 $149,964 - $181,396	8,080 Added 82.3%	17,898 $385,000
Q1 2018 Apr 26, 2018	BUY	$22.15 - $31.89 $575 - $829	26 Added 0.27%	9,818 $0
Q4 2017 Feb 01, 2018	SELL	$24.23 - $30.93 $2.89 Million - $3.69 Million	-119,282 Reduced 92.41%	9,792 $297,000
Q4 2017 Jan 29, 2018	BUY	$24.23 - $30.93 $3.13 Million - $3.99 Million	129,074	129,074 $286,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Ifg Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Ifg Advisory, LLC with notifications on news.